SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00Dec 24 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (199)12/10/1997 10:38:00 PM
From: John Dwyer  Read Replies (1) of 1494
 
Thanks John,
I agree with the idea that this is related to tax-loss selling. The
threat of delisting combined with NTII's cash crunch makes this stock
an easy target.

John, do you think that a secondary is really the best idea for
NTII? To fund a Phase III trial they need significant cash... a
secondary would imply a high degree of dilution. Wouldn't a
partnership be better for them? Do you think there is any chance
of a decent deal considering NTII's weakened finacial state? Perhaps
they are waiting for the results before striking a deal. Comments?

John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News